SoftOx småprat

[Hotdog]

Rart at kursen ikke er 20 øre - da det snart kommer noen hundre millioner aksjer til kjøpspris 20 øre. Sikkert seleco som daytrader.

[XCR]

Kaos

[Hotdog]

Seleco som daytrader og tjener litt penger.

[TekBot]

SOFTX; Subscription of shares in private placement/debt conversion and grant of share warrants to primary insiders

Please see attachement for further information.
…

Vis børsmeldingen

Kilde

[KrissKross]

Ned 47% med 22 kroner i omsetning. Humor.

[TekBot]

SOFTX: New share capital

Not for release, publication or distribution, in whole or in part directly or indirectly, in Australia, Canada, Japan or the United States (or any other jurisdiction in which the release, publication or distribution would be unlawful). This announcement does not constitute an offer of any of the securities described herein.
Reference is made to the stock exchange release from Softox Solutions AS (the “Company”) 27 March 2024 regarding share capital increase resolved be the general meeting.
The new share capital following completion of the private placement and the debt conversion has today been registered with the Norwegian Register of Business Enterprises.
…

Vis børsmeldingen

The new share capital of the Company is NOK 10 068 473.80 divided on 503 423 690 shares with a nominal value of NOK 0.02 per share.
Note that there is a minimal deviation from the registered (and correct) new share capital and number of shares issued compared to information in the stock exchange release 27 March 2024.
For any questions or interview requests, please contact:
Geir Almås, Chair of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Geir Almås: (+47) 977 59 071
About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on Euronext Growth Oslo under ‘SOFTX’. SoftOx Solutions AS was founded in 2012 and is headquartered in Oslo. The SoftOx Solutions Group includes: the holding company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly effective antimicrobial solution for use in biofilm, viral and antimicrobial resistant infections. The patent-protected technology is based on extensive research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com

Kilde

[peter_ross]

Litt av ei topp 50 liste som kom nå. Topp 50 eier nå 99,1 % av aksjene i selskapet.

[peter_ross]

[tverilytt]

@peter_ross

Topp 50 eier nå 99,1 % av aksjene i selskapet.

Mon tro om noen av de har tenkt å selge litt?

[TekBot]

SoftOx Solutions AS: Commencement of the subscription period for the Subsequent Offering

Not for release, publication or distribution, in whole or in part directly or indirectly, in Australia, Canada, Japan or the United States (or any other jurisdiction in which the release, publication or distribution would be unlawful). This announcement does not constitute an offer of any of the securities described herein.

Oslo, Norway, 15 April 2024: Reference is made to the previous stock exchange announcements from SoftOx Solutions AS (the “Company”) regarding the completion of the private placement and the contemplated subsequent offering (the “Subsequent Offering”) as described therein.
…

Vis børsmeldingen

The subscription period in the Subsequent Offering commences today, Monday 15 April 2024 at 09:00 hours (CEST) and will end on 29 April 2024 at 16:30 hours (CEST) (the “Subscription Period”).

The Subsequent Offering consists of an offering of up to 125,000,000 shares (the “Offer Shares”) in the Company at a subscription price of NOK 0.2 per Offer Share. The Subsequent Offering is directed towards existing shareholders in the Company as of March 27 2024, as registered in the Company’s shareholder register at Euronext Securities Oslo (VPS) on 3 April 2024 (“Record Date”), and who (i) were not included in the pre-sounding phase of the private placement, (ii) were not allocated offer shares in the private placement, and (iii) are not resident in a jurisdiction where such an offer would be illegal or would (in jurisdictions other than Norway) require a prospectus, filing, registration, or similar action (the “Eligible Shareholders”)

Each Eligible Shareholder will receive 12.644 non-tradeable subscription rights (the “Subscription Rights”) for each share held by such Eligible Shareholder in the Company as of the Record Date. Each Subscription Right gives, subject to certain limitations based on applicable laws and regulations, the right to subscribe for, and be allocated one (1) Offer Share in the Subsequent Offering at the Offer Price. The number of Subscription Rights granted to each Eligible Shareholder will be rounded down to the nearest whole Subscription Right. Over-subscription is allowed. Subscription without Subscription Rights is not allowed.

In order to subscribe for Offer Shares, you must either send in a complete and duly signed subscription form to the Manager (as defined below) or subscribe thought VPS online subscription system available for Norwegian citizens, within the end of the Subscription Period. Further instructions regarding the subscription procedure are available in the Prospectus that has been registered with the Norwegian Register of Business Enterprises.

Subscription Rights that are not exercised before 16.30 CEST on 29 April 2024 will have no value and will lapse without compensation to the holder.

The due date for payment of the Offer Shares is 2 May 2024. The Offer Shares will, after registration of the share capital increase in the Norwegian Register of Business Enterprises pertaining to the Offer Shares, be registered in the VPS in book-entry form and are expected to be delivered to the applicant’s VPS account on or about 10 May 2024. The Offer Shares will have equal rights and rank pari passu with the Company’s other shares.

Please see the Prospectus for more information about the Subsequent Offering. The Prospectus, including a subscription form, is made electronically available at www.soft-ox.com and www.sb1markets.no.

Sparebank 1 Markets (“Manager”) is acting as Manager in the Subsequent Offering. Kvale Advokatfirma acts as legal advisor in the Subsequent Offering,

For any questions or interview requests, please contact:
Geir Almås, Chair of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Geir Almås: (+47) 977 59 071
About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on Euronext Growth Oslo under ‘SOFTX’. SoftOx Solutions AS was founded in 2012 and is headquartered in Oslo. The SoftOx Solutions Group includes: the holding company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly effective antimicrobial solution for use in biofilm, viral and antimicrobial resistant infections. The patent-protected technology is based on extensive research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com

Kilde

[TekBot]

Soft-Ox Solutions AS: Receipt of subscription rights in the subsequent offering by primary insiders and their close associates

Oslo, Norway, 15 April 2024: Reference is made to the stock exchange announcement published by Soft-Ox Solutions AS (the “Company”) today regarding the Subsequent Offering.
The following subscription rights in the Company have been allocated to primary insiders / closely associates of the Company:
Name and position Allocated subscription rights
…

Vis børsmeldingen

Geir Almås Chairman Board 1) 9,359,920
Olav Jarlsby, Board member 304,722
Ingrid Juven (COM) 2) 885,086

The subscription rights are allocated to his/hers wholly owned subsidiary:

1. Hermod Farms AS
2. Bonica AS

Each subscription right gives the right to subscribe for and be allocated one offer share in the Subsequent Offering at a subscription price of NOK 0.2 per share.
This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

Kilde

[Olympus]

Noen som har tenkt å bli med videre i dette svindelforetaket?

[Hotdog]

Ser ingen grunn til å eie aksjer i selskapet, spesielt ikke når sårselskapet er tatt ut og med den historikken selskapet og ledelsen har.

[BATINE]

Vet noen noe mer om hva som skjer med de nye aksjene man skulle få, dersom man eide aksjer før de splittet opp selskapet?

[Mrodseth]

Presentation of The New SoftOx Solutions AS

Thu, 18 Apr 13:00 CEST

Vi har besøk av Softox Solutions igjen:

https://investorweb.no/ir-channel/SOFTX/event /6ed5ce14-12e5-4e6f-8a4c-8ea9afd913bb

Today’s presentation will mainly focus on presenting SoftOx Inhalation AS.

Husk å bruke Q&A-funksjonen i menyen for å stille spørsmål.

[polsmannen]

Eneste som er helt klart er at dette ikke er den siste utvanningen av eksisterende småaksjonærer. Var det drift å vedlikehold i 3-6 måneder de hadde etter denne runden?

[Olympus]

Her bør en holde seg langt unna for med en ledelse som ikke har prestert annet en emisjon på emisjon , løgn på løgn og klart å kjøre selskapet i grøfta på denne måten kan EM-billetten bruke mer penger på.
De hauset til de grader men klarte ikke engang å få godkjenning for produktene som er ustabile og ikke holder mål.

[polsmannen]

Edit. Leste gjennom gamle eposter og fant den å det gjaldt en epost.

[TekBot]

SoftOx Solutions AS Presentation of “The New SoftOx” at Investorweb.no Thursday the 18th of April 1 pm

Presentation of “The New SoftOx” at

https://investorweb.no/ir-channel/SOFTX/event - Thursday the 18th of April 1 pm.
…

Vis børsmeldingen

The presentation will be recorded and made available afterwards.

SoftOx Solutions AS has been through a rough period. Over the last one and a half years the Company has been forced to make drastic changes. A new strategy has been developed. The term “New SoftOx” is internally used to mark this shift in strategy.

An important milestone in this work was to refinance the Company. Nearly all debt is now converted to shareholder capital. The former shareholders are now given the right to participate in this refinancing on similar terms as the debt holders.

The “new SoftOx” will aim to disrupt today’s infection treatment in respiratory and chronic wounds, building on the unique properties of the SoftOx technology. Clinical experiments and product development will be conducted in close cooperation with our partners under supervision of project leaders from SoftOx.

With the new strategy the Company has significantly reduced the running costs. The manning is reduced to a slim organization that will manage outsourced research and development.

The Board recommends that SoftOx Solutions AS will be split into two entities. This sets the condition to be focused on two different segments.

Today’s presentation will mainly focus on presenting the business area SoftOx Inhalation AS. SoftOx Solutions AS will be renamed to SoftOx Inhalation AS, and will remain being listed on Oslo Euronext Growth. The company will develop a solution to treat Ventilator Associated Pneumonia (VAP) in patients admitted to intensive care. VAP is a frequent and lethal threat to patients on ventilators. In addition, SoftOx Inhalation will continue the important work with our partners in the European Defence Fund (EDF) to develop a countermeasure to protect soldiers against biological warfare agents spread through the respiratory system. The defense project is fully financed by EDF, all commercial rights will be the property of SoftOx. Both VAP and EDF projects will outsource the research and development to the University of Copenhagen.

Welcome.

Kilde

[XCR]

New Softox